| Bid | 36.6 |
| Market Cap | 3.89B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -2.36 |
| PE Ratio (ttm) | -17.59 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 47.91 |
| Volume | 501,828 |
| Avg. Volume (20D) | 1,111,022 |
| Open | 43.17 |
| Previous Close | 42.60 |
| Day's Range | 40.75 - 43.59 |
| 52-Week Range | 6.76 - 46.19 |
| Beta | undefined |
About SRRK
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical tria...
Analyst Forecast
According to 7 analyst ratings, the average rating for SRRK stock is "Buy." The 12-month stock price forecast is $42, which is an increase of 1.16% from the latest price.
2 months ago · seekingalpha.com
Scholar Rock Holding Corporation (SRRK) Q3 2024 Earnings Call TranscriptScholar Rock Holding Corporation (NASDAQ:SRRK ) Q3 2024 Earnings Conference Call November 12, 2024 8:15 AM ET Company Participants Jay Backstrom - President & CEO Ted Myles - COO & CFO Conference Call...
